Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the phase 3 EVOKE-03/KEYNOTE-D46 trial presented…
A recent phase 3 trial demonstrated that sacituzumab govitecan combined with pembrolizumab did not improve progression-free survival compared to pembrolizumab alone in patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or higher. While the combination therapy showed a higher response rate, the difference in progression-free survival did not meet statistical significance.
Overall survival also did not improve significantly when comparing the combined treatment to pembrolizumab monotherapy at the interim analysis. The study enrolled 620 patients and found higher treatment-related adverse events with the combination, including anemia, alopecia, neutropenia, diarrhea, and nausea.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
